CJC-1295
Also known as: Modified GRF 1-29, Mod GRF 1-29, CJC-1295 DAC, CJC-1295 no-DAC
Short-acting GHRH analog (Modified GRF 1-29) that stimulates natural GH pulses from the pituitary. Daily bedtime dosing, commonly paired with Ipamorelin. The DAC variant binds albumin for weekly dosing but blunts pulsatility.
Pharmacokinetics
- Half-life
- 30 min
- Time to peak
- 30 min
- Bioavailability
- 95%
- Onset
- 30 min
- Dosing interval
- 24h
Administration
- Primary routes
- SubQ
- Category
- Growth Hormone Secretagogues
Safety Flags
- High immunogenicity
- Contraindicated in cancer history
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 4 outcome protocols
- Muscle Growth
Optimize muscle protein synthesis and growth hormone release for enhanced muscle development
Safe default: 100mcg · daily · SubQ
- Fat Loss (Lipolysis)
Accelerate fat metabolism and lipolysis without affecting growth hormone levels
Safe default: 100mcg · daily · SubQ
- Injury Repair
Accelerate healing of tendons, ligaments, muscles, and other soft tissues
Safe default: 100mcg · daily · SubQ
- Sleep Quality
Improve sleep architecture and quality of rest
Safe default: 100mcg · daily · SubQ
Simulate CJC-1295
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.